他汀类药物在慢性阻塞性肺疾病治疗中的研究进展

Research progress of role of statins in treatment of chronic obstractive pulmonary disease

慢性阻塞性肺疾病(COPD)是一种具有气流受限特征的可以预防和治疗的疾病。气流受限不完全可逆,呈进行性发展,与肺部对有害气体或颗粒的异常炎症反应有关。他汀类药物是3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂,是最为经典和有效的降脂药物,广泛应用于心血管疾病的治疗。近年来研究发现,他汀类药物通过抗金属蛋白酶、抗氧化、抗炎症介质及细胞因子、抑制黏附分子表达、降低C反应蛋白等环节起到抗炎作用,缓解了COPD患者的肺功能,降低了发病率和病死率。

Chronic obstructive pulmonary disease（COPD） is characterized by progressive and minimally reversible airflow limitation with systemic inflammation,which can be prevented and treated.Statins reduce cholesterol levels by inhibiting 3-hydroxy-3-methlglutaryl coenzyme A（HMG-CoA） reductase,and have an established role in the treatment of cardiovascular diseases.Recent studies have revealed that statins have profound anti-inflammatory effects by reducing induction of matrix metalloproteinase,expression of cytokines and cell adhesion molecules,antioxidant state and C-reactive protein,which decreases lung function deterioration,morbidity and mortality in COPD.